Table 49. Patient characteristics–trifluoperazine versus clozapine

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Rinieris et al. 1980**157 | ***Study design:*** RCT***Registration #:*** NR***Study population:*** Schizophrenia***DSM Classification:*** NR***Study period:*** NR***Number of centers:*** Single center***Setting:*** Inpatient***Country:*** Greece***Financial support:*** NR***Washout period performed:*** NA***Run-in phase performed:*** yes (1 wk)***Followup period:*** 6 wks |  ***Main inclusion criteria:*** Sz pts with absence of clinical symptoms; no Hx of thyroid or endocrinological disease; no use of psychotropic meds***Main exclusion criteria:*** NR | ***G1:******Age (mean±SD):*** 27.30±9.00***Males (n(%)):*** NR***Ethnicity:*** NR***BL symptom scores:*** BPRS (mean±SD): 41.5±9.3***G2:******Age (mean±SD):*** 27.30±9.00***Males (n(%)):*** NR***Ethnicity:*** NR***BL symptom scores:*** BPRS (mean±SD): 40.5±10***G3:******Age (mean±SD):*** 27.30±9.00***Males (n(%)):*** NR***Ethnicity:*** NR***BL symptom scores:*** BPRS (mean±SD): 36.4±11.4 | ***G1:******Classification:*** FGA***Drug:*** Chlorpromazine***Dosage:*** 50–100mg***Intervals:*** TID***G2:******Classification:*** FGA***Drug:*** Trifluoperazine***Dosage:*** 2.5–5mg***Intervals:*** TID***G3:******Classification:*** SGA***Drug:*** Clozapine***Dosage:*** 50–100mg***Intervals:*** TID |

AP = antipsychotic; BL = baseline; BPRS = Brief Psychiatric Rating Scale; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; DX = diagnosis; FGA = first-generation antipsychotic; Hx = history; mg = milligram; n = number; NR = not reported; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; TID = Three times daily; wk = week; yr = year